Healthcare / Drug Manufacturers - Specialty & GenericNasdaqCM
$0.48
-0.00 (-0.82%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-1.8M · quality 68.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
12/100
F
Piotroski
0/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$5M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-42.0%
↓Gross Margin
N/A
•Debt/Equity
0.27
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+3.9%
FCF CAGR
—
FCF margin
-3721.1%
FCF / Net income
0.93x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $165645.0 · net income $-6.6M · FCF $-6.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $165645.00 | $165645.00 | — | $79843.00 | $147536.00 |
| Net Income | $-6.6M | $-6.6M | $-3.5M | $-3.5M | $-3.4M |
| EBITDA | $-3.5M | $-3.5M | $-1.7M | $-1.9M | $-2.0M |
| EPS | — | — | -0.38 | -0.37 | -0.36 |
| Gross Margin | — | — | — | 38.7% | 35.7% |
| Operating Margin | -2989.0% | -2989.0% | — | -4232.9% | -2165.1% |
| Net Margin | -4011.9% | -4011.9% | — | -4391.4% | -2283.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.27 | 0.27 | 0.25 | 0.13 | 0.07 |
| Current Ratio | 0.27 | 0.27 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-6.2M | $-6.2M | $-1.2M | $-1.8M | $-1.5M |
| Returns | |||||
| ROE | -42.0% | -42.0% | -23.5% | -18.8% | -16.2% |
| Valuation | |||||
| P/B | 0.31 | 0.31 | — | — | — |
| Growth & Yield | |||||
| Revenue Growth | — | — | — | -45.9% | — |
| EPS Growth | — | — | -1.1% | -4.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-69.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.38 → n/d
Residual
-69.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.